Evidence map›Paper›PMID 27404186›Full record

ArticleJAMA2016

Association of Medical Male Circumcision and Antiretroviral Therapy Scale-up With Community HIV Incidence in Rakai, Uganda.

Xiangrong Kong, Godfrey Kigozi, Joseph Ssekasanvu, Fred Nalugoda, Gertrude Nakigozi, Anthony Ndyanabo, Tom Lutalo, Steven J Reynolds, Robert Ssekubugu, Joseph Kagaayi and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in JAMA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Xiangrong KongDepartment of Epidemiology, Johns Hopkins, Bloomberg School of Public Health, Baltimore, Maryland2Department of Biostatistics, Johns Hopkins, Bloomberg School of Public Health, Baltimore, Maryland.
Godfrey KigoziRakai Health Sciences Program, Entebbe, Uganda.
Joseph SsekasanvuDepartment of Epidemiology, Johns Hopkins, Bloomberg School of Public Health, Baltimore, Maryland3Rakai Health Sciences Program, Entebbe, Uganda.
Fred NalugodaRakai Health Sciences Program, Entebbe, Uganda.
Gertrude NakigoziRakai Health Sciences Program, Entebbe, Uganda.
Anthony NdyanaboRakai Health Sciences Program, Entebbe, Uganda.
Tom LutaloRakai Health Sciences Program, Entebbe, Uganda.
Steven J ReynoldsJohns Hopkins School of Medicine, Baltimore, Maryland5Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Robert SsekubuguRakai Health Sciences Program, Entebbe, Uganda.
Joseph KagaayiRakai Health Sciences Program, Entebbe, Uganda.
Eva BugosDepartment of Epidemiology, Johns Hopkins, Bloomberg School of Public Health, Baltimore, Maryland.
Larry W ChangDepartment of Epidemiology, Johns Hopkins, Bloomberg School of Public Health, Baltimore, Maryland4Johns Hopkins School of Medicine, Baltimore, Maryland.
Pilgrim NanlestaPopulation Council, Washington, DC.
Grabowski MaryDepartment of Epidemiology, Johns Hopkins, Bloomberg School of Public Health, Baltimore, Maryland.
Amanda BermanCenter for Communications Programs, Johns Hopkins, Baltimore, Maryland.
Thomas C QuinnJohns Hopkins School of Medicine, Baltimore, Maryland5Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
David SerwaddaRakai Health Sciences Program, Entebbe, Uganda8School of Public Health, Makerere University, Kampala, Uganda.
Maria J WawerDepartment of Epidemiology, Johns Hopkins, Bloomberg School of Public Health, Baltimore, Maryland3Rakai Health Sciences Program, Entebbe, Uganda.
Ronald H GrayDepartment of Epidemiology, Johns Hopkins, Bloomberg School of Public Health, Baltimore, Maryland3Rakai Health Sciences Program, Entebbe, Uganda.
Rakai Health Sciences Program · UGJohns Hopkins University · USNational Institute of Allergy and Infectious Diseases · USPopulation Council · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Circumcision: HIV/STIs and behaviors in a RCT and post-RCT surveillance; RakaiU01AI075115 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2007 to 2011
$9.3M
ARV effects on HIV epidemiology &behaviors Rakai UgandaR01HD050180 · NICHD · JOHNS HOPKINS UNIVERSITY · PI WAWER, MARIA J · 2005 to 2009
$7.8M
Enhanced Provision of Male Circumcision for HIV Prevention, Rakai, UgandaU01AI100031 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2012 to 2014
$3.2M
The Problem With Male Sexual/Repro Health:Qualitative/Quantitative Study, UgandaR01HD070769 · NICHD · JOHNS HOPKINS UNIVERSITY · PI WAWER, MARIA J · 2011 to 2013
$1.4M
Male Circumcision and Use of Foreskin Tissues for HIV Prevention in UgandaD43TW009578 · FIC · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2013 to 2017
$1.3M
Multilevel determinants of male circumcision uptake, Rakai, UgandaK25AI114461 · NIAID · UNIVERSITY OF MASSACHUSETTS AMHERST · PI KONG, XIANGRONG · 2014 to 2017
$515k
FIC NIH HHS D43 TW009578Intramural NIH HHSNIAID NIH HHS K25 AI114461NIAID NIH HHS K25AI114461NIAID NIH HHS P30 AI094189NIAID NIH HHS U01 AI075115NIAID NIH HHS U01AI075115NIAID NIH HHS U01 AI100031NIAID NIH HHS U01AI100031NICHD NIH HHS R01 HD050180NICHD NIH HHS R01HD050180NICHD NIH HHS R01 HD070769
6 · The paper itself

Abstract

importanceMedical male circumcision (MMC) and antiretroviral therapy (ART) are proven HIV prevention interventions, but there are limited data on the population-level effect of scale-up of these interventions in sub-Saharan Africa. Such evaluation is important for planning and resource allocation.

objectiveTo examine whether increasing community MMC and ART coverage was associated with reduced community HIV incidence in Rakai District, Uganda. DESIGN, SETTING, AND

participantsUsing person-level data from population-based surveys conducted from 1999 through 2013 in 45 rural Rakai communities, community-level ART and MMC coverage, sociodemographics, sexual behaviors, and HIV prevalence and incidence were estimated in 3 periods: prior to the availability of ART and MMC (1999-2004), during early availability of ART and MMC (2004-2007), and during mature program scale-up (2007-2013). EXPOSURES: Community MMC coverage in males and ART coverage in HIV-positive persons of the opposite sex based on self-reported MMC status and ART use. MAIN OUTCOMES AND MEASURES: Adjusted incidence rate ratios (IRRs) for sex-specific community HIV incidence estimated using multivariable Poisson regression with generalized estimating equations.

resultsFrom 1999 through 2013, 44,688 persons participated in 1 or more surveys (mean age at the first survey, 24.6 years [range, 15-49]; female, 56.5%; mean survey participation rate, 92.6% [95% CI, 92.4%-92.7%]). Median community MMC coverage increased from 19% to 39%, and median community ART coverage rose from 0% to 21% in males and from 0% to 26% in females. Median community HIV incidence declined from 1.25 to 0.84 per 100 person-years in males, and from 1.25 to 0.99 per 100 person-years in females. Among males, each 10% increase in community MMC coverage was associated with an adjusted IRR of 0.87 (95% CI, 0.82-0.93). Comparing communities with MMC coverage more than 40% (mean male community incidence, 1.03 per 100 person-years) with communities with coverage of 10% or less (mean male incidence, 1.69 per 100 person-years), the adjusted IRR was 0.61 (95% CI, 0.43-0.88). For each 10% increase in female self-reported ART coverage, there was no significant reduction in male HIV incidence (adjusted IRR, 0.95 [95% CI, 0.81-1.13]). Comparing communities with female ART coverage more than 20% (mean male incidence, 0.87 per 100 person-years) to communities with female ART coverage of 20% or less (mean male incidence, 1.17 per 100 person-years), the adjusted IRR was 0.77 (95% CI, 0.61-0.98). Neither MMC nor male ART coverage was associated with lower female community HIV incidence. CONCLUSIONS AND RELEVANCE: In Rakai, Uganda, increasing community MMC and female ART coverage was associated with lower community HIV incidence in males. If similar associations are found elsewhere, this would support further scale-up of MMC and ART for HIV prevention in sub-Saharan Africa.

Indexed as

Circumcision, MaleAdolescentAdultAnti-Retroviral AgentsFemaleHealth SurveysHIV InfectionsHumansIncidenceMaleMiddle AgedPrevalenceResidence CharacteristicsRural PopulationSex FactorsSexual BehaviorAnti-Retroviral Agents

Identifiers

PMID27404186
PMCPMC5027874
OpenAlexW2463012500

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.